| Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret … AA Garcia, H Hirte, G Fleming, D Yang, DD Tsao-Wei, L Roman, ... Journal of Clinical Oncology 26 (1), 76-82, 2008 | 679 | 2008 |
| Primary tumor location as a prognostic factor in metastatic colorectal cancer F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ... Journal of the National Cancer Institute 107 (3), dju427, 2015 | 528 | 2015 |
| Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models Y Ning, PC Manegold, YK Hong, W Zhang, A Pohl, G Lurje, T Winder, ... International journal of cancer 128 (9), 2038-2049, 2011 | 523 | 2011 |
| A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer J Stoehlmacher, DJ Park, W Zhang, D Yang, S Groshen, S Zahedy, ... British journal of cancer 91 (2), 344-354, 2004 | 512 | 2004 |
| Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis YS Lee, I Choi, Y Ning, NY Kim, V Khatchadourian, D Yang, HK Chung, ... British journal of cancer 106 (11), 1833-1841, 2012 | 322 | 2012 |
| Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity D Yang, A Hendifar, C Lenz, K Togawa, F Lenz, G Lurje, A Pohl, T Winder, ... Journal of gastrointestinal oncology 2 (2), 77, 2011 | 261 | 2011 |
| Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia I Aldoss, D Yang, A Aribi, H Ali, K Sandhu, MM Al Malki, M Mei, A Salhotra, ... Haematologica 103 (9), e404, 2018 | 237 | 2018 |
| Gender disparities in metastatic colorectal cancer survival A Hendifar, D Yang, F Lenz, G Lurje, A Pohl, C Lenz, Y Ning, W Zhang, ... Clinical Cancer Research 15 (20), 6391-6397, 2009 | 233 | 2009 |
| Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab AM Schultheis, G Lurje, KE Rhodes, W Zhang, D Yang, AA Garcia, ... Clinical Cancer Research 14 (22), 7554-7563, 2008 | 208 | 2008 |
| BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ... British journal of cancer 112 (12), 1921-1928, 2015 | 175 | 2015 |
| Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis D Yang, DL Hanna, J Usher, J LoCoco, P Chaudhari, HJ Lenz, ... Cancer 120 (23), 3707-3716, 2014 | 153 | 2014 |
| Influence of sex on the survival of patients with esophageal cancer P Bohanes, D Yang, RS Chhibar, MJ Labonte, T Winder, Y Ning, A Gerger, ... Journal of Clinical Oncology 30 (18), 2265, 2012 | 151 | 2012 |
| Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer G Giamas, A Filipović, J Jacob, W Messier, H Zhang, D Yang, W Zhang, ... Nature medicine 17 (6), 715-719, 2011 | 151 | 2011 |
| Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression S Swenson, F Costa, R Minea, RP Sherwin, W Ernst, G Fujii, D Yang, ... Molecular Cancer Therapeutics 3 (4), 499-511, 2004 | 148 | 2004 |
| Piecewise growth curve modeling approach for longitudinal prevention study CP Chou, D Yang, MA Pentz, YI Hser Computational Statistics & Data Analysis 46 (2), 213-225, 2004 | 144 | 2004 |
| Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer … G Lurje, F Nagashima, W Zhang, D Yang, HM Chang, MA Gordon, ... Clinical Cancer Research 14 (23), 7884-7895, 2008 | 132 | 2008 |
| The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models Y Ning, MJ Labonte, W Zhang, PO Bohanes, A Gerger, D Yang, ... Molecular cancer therapeutics 11 (6), 1353-1364, 2012 | 127 | 2012 |
| A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. AB El-Khoueiry, Y Ning, D Yang, S Cole, M Kahn, M Zoghbi, J Berg, ... Journal of Clinical Oncology 31 (15_suppl), 2501-2501, 2013 | 123 | 2013 |
| Outcome disparities in multiple myeloma: a SEER‐based comparative analysis of ethnic subgroups S Ailawadhi, IT Aldoss, D Yang, P Razavi, W Cozen, T Sher, ... British journal of haematology 158 (1), 91-98, 2012 | 118 | 2012 |
| Generation of a concise gene panel for outcome prediction in urinary bladder cancer AP Mitra, V Pagliarulo, D Yang, FM Waldman, RH Datar, DG Skinner, ... Journal of clinical oncology 27 (24), 3929, 2009 | 115 | 2009 |
